海外の治験の状況「前立腺癌」での検索結果
266件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Estonia, France, Germany, Greece, India, Israel, Italy, Korea, Republic of, Latvia, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Panama, Peru, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Province of China, Turkey, Ukraine, United Kingdom, United States
- 2015-04-30
Not Recruiting
- A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- -C61 Malignant neoplasm of prostate Malignant neoplasm of prostate;Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea South, Latvia, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States
- 2015-04-29
Not Recruiting
- Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hungary, Korea, Republic of, Netherlands, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, Province of China, Tunisia, Turkey, United Kingdom, United States
- 2015-03-11
Not recruiting
- Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer
- Prostate Cancer Non-Metastatic;Castration-Resistant
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2014-07-22
Not recruiting
- Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET
- Prostate Cancer
- Australia, Canada, Ireland, New Zealand, United Kingdom, United States of America
- 2014-01-29
Not recruiting
- A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
- Prostate Neoplasms
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
- 2012-10-24
Not recruiting
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Metastatic Castration-resistant Prostate Cancer
- Argentina, Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2016-11-15
Not recruiting
- Phase II pre-operative study of ‘super-castration’ with combination Degarelix, Abiraterone, Bicalutamide and Prednisone in high-risk localized prostate cancer.
- Prostate cancer
- Australia
- 2012-07-20
Not recruiting
- A randomised controlled trial of an interactive decision aid for prostate cancer screening
- PSA testing for prostate cancer.
- Australia
- 2012-07-06
Not Recruiting
- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Australia, Belgium, Canada, France, Germany, Greece, Netherlands, Spain, Sweden, United Kingdom, United States
- 2012-06-18